|
Feb 16
|
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Feb 14
|
Immunome Announces Pricing of Public Offering of Common Stock
|
|
Feb 13
|
Immunome Announces Proposed Public Offering of Common Stock
|
|
Feb 10
|
Insiders See US$1.25m Investment In Immunome Jump Last Week
|
|
Feb 7
|
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
|
|
Feb 6
|
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
|
|
Feb 5
|
Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
|
|
Jan 8
|
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform
|
|
Jan 4
|
Immunome Appoints Phil Roberts as Chief Technical Officer
|
|
Jan 3
|
Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Nov 8
|
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors
|
|
Oct 1
|
Individual investors who hold 51% of Immunome, Inc. (NASDAQ:IMNM) gained 15%, institutions profited as well
|